RCTS Randomized Clinical Trials
RCTS Randomized Clinical Trials is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
A phase III study to assess efficacy and safety of N-Acetyl-GED-0507-34-LEVO gel 5%, applied once daily for 12 weeks in patients with acne vulgaris (GEDACNE-1)
Sponsor PPM Services S.A.
- Start (EU)
- Latest update
- Estimated end
A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Sponsor Y-mAbs Therapeutics A/S
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Multicentric Randomized Double-Blinded Efficacy and Safety Clinical Trial Comparing Several Doses of Aganirsen Eye Drops Emulsion to Extend Intravitreal Aflibercept Treatment Interval in Wet Age-Related Macular Degeneration (wAMD) Patients - SKY2 Study
Sponsor Laboratoires Kol
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A long-term safety and efficacy study of N-Acetyl-GED-0507-34-LEVO gel 5%, in subjects with acne vulgaris (GEDACNE-LT)
Sponsor PPM Services S.A.
- Start (EU)
- Latest update
- Estimated end
A multicentre, intra-patient randomised controlled Phase III study to confirm the efficacy and safety of denovoSkin™, a bilayer engineered collagen-based skin graft composed of autologous fibroblasts and keratinocytes, for the treatment of patients with deep partial and full-thickness burns
Sponsor Cutiss AG
- Start (EU)
- Latest update
- Estimated end
A phase III study to assess efficacy and safety of N-Acetyl-GED-0507-34-LEVO gel 5%, applied once daily for 12 weeks in patients with acne vulgaris (GEDACNE-2)
Sponsor PPM Services S.A.
- Start (EU)
- Latest update
- Estimated end
A Phase II Proof of Concept Multicenter, Randomized, Double-Blind Study to assess the safety and efficacy of Phage Therapy in Patients with Hip or Knee Prosthetic Joint Infection due to Staphylococcus aureus Treated by DAIR
Sponsor Phagenix
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase II, multi-center, prospective, open-label study of Asciminib in patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) or accelerated Phase (CML-AP) with T315I mutation who are resistant, intolerant or ineligible to ponatinib (ASC4TARGET)
Sponsor Novartis Pharma S.A.S.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for RCTS Randomized Clinical Trials?
The 2026-10-09 snapshot links RCTS Randomized Clinical Trials to 8 distinct CTIS trials. Recorded services include Clinical monitoring, Investigator recruitment, Project management, Regulatory services, among 12 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for RCTS Randomized Clinical Trials?
The most frequently recorded therapeutic areas are Dermatology, Solid Tumor Oncology. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to RCTS Randomized Clinical Trials conducted?
The linked trials record locations in 9 countries, including France, Spain, Italy, Poland, Germany. These are trial locations, not confirmed office locations or countries where RCTS Randomized Clinical Trials delivered services.
What can this page tell me about RCTS Randomized Clinical Trials's trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under RCTS Randomized Clinical Trials. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- RCTS Randomized Clinical Trials